Raras
Buscar doenças, sintomas, genes...
Esfingolipidose
ORPHA:79225CID-11 · 5C56.0DOENÇA RARA

Distúrbio metabólico hereditário que afeta a degradação lisossomal dos espingolipídeos. Exemplos representativos incluem a doença de Gaucher, a doença de Tay-Sachs e a doença de Niemann-Pick.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Distúrbio metabólico hereditário que afeta a degradação lisossomal dos espingolipídeos. Exemplos representativos incluem a doença de Gaucher, a doença de Tay-Sachs e a doença de Niemann-Pick.

Publicações científicas
171 artigos
Último publicado: 2026 Apr 1
Medicamentos
8 registrados
MIGALASTAT HYDROCHLORIDE, MIGLUSTAT, ELIGLUSTAT

Tem tratamento?

8 medicamentos registrados
Ver detalhes, fases e interações →
MIGALASTAT HYDROCHLORIDEMIGLUSTATELIGLUSTATTORIPALIMABATIDARSAGENE AUTOTEMCELVENGLUSTATMIGALASTATLUCERASTAT
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
114 sintomas
🦴
Ossos e articulações
63 sintomas
❤️
Coração
37 sintomas
👁️
Olhos
37 sintomas
💪
Músculos
31 sintomas
🫃
Digestivo
31 sintomas

+ 306 sintomas em outras categorias

Características mais comuns

Formato facial anormal
Hemorragia nasal
Aumento da beta-hexosaminidase sérica
Mania
Fraqueza dos flexores do quadril
Crise focal com alteração da consciência
760sintomas
Sem dados (760)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 760 características clínicas mais associadas, ordenadas por frequência.

Formato facial anormalAbnormal facial shape
Hemorragia nasalHP:6001353
Aumento da beta-hexosaminidase séricaIncreased serum beta-hexosaminidase
Mania
Fraqueza dos flexores do quadrilHip flexor weakness

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico171PubMed
Últimos 10 anos64publicações
Pico201910 papers
Linha do tempo
2026Hoje · 2026🧪 1988Primeiro ensaio clínico📈 2019Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

17 genes identificados com associação a esta condição.

GBA1Lysosomal acid glucosylceramidaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramides/GlcCers (such as beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine) into free ceramides (such as N-acylsphing-4-enine) and glucose (PubMed:15916907, PubMed:24211208, PubMed:32144204, PubMed:39395789, PubMed:9201993). Plays a central role in the degradation of complex lipids and the turnover of cellular membranes (PubMed:27378698). Through the production of ceramides, participates in the PKC-activ

LOCALIZAÇÃO

Lysosome membrane

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

Gaucher disease

An autosomal recessive lysosomal storage disease due to deficient activity of lysosomal beta-glucocerebrosidase, and characterized by accumulation of glucosylceramide in the reticulo-endothelial system. GD is a multisystem disease historically divided into three main subtypes on the basis of the presence of neurologic involvement, age at onset and progression rate: type 1 is the non-neuropathic form, type 2 is the acute neuropathic form with early onset and rapid neurologic deterioration, type 3 is the chronic neuropathic form with slow progression of neurologic features. GD shows a marked phenotypic diversity ranging from adult asymptomatic forms, at the mild end, to perinatal lethal forms at the severe end of the disease spectrum. Formal diagnosis of Gaucher disease is based on the measurement of glucocerebrosidase levels in circulating leukocytes and molecular genetic analysis.

OUTRAS DOENÇAS (7)
Gaucher disease type IIGaucher disease perinatal lethalGaucher disease-ophthalmoplegia-cardiovascular calcification syndromeGaucher disease type I
HGNC:4177UniProt:P04062
GBA2Non-lysosomal glucosylceramidaseCandidate gene tested inTolerante
FUNÇÃO

Non-lysosomal glucosylceramidase that catalyzes the hydrolysis of glucosylceramides/GlcCers (such as beta-D-glucosyl-(1<->1')-N-acylsphing-4-enine) to free glucose and ceramides (such as N-acylsphing-4-enine) (PubMed:17105727, PubMed:30308956, PubMed:32144204). GlcCers are membrane glycosphingolipids that have a wide intracellular distribution (By similarity). They are the main precursors of more complex glycosphingolipids that play a role in cellular growth, differentiation, adhesion, signaling

LOCALIZAÇÃO

Endoplasmic reticulum membraneGolgi apparatus membrane

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

Spastic paraplegia 46, autosomal recessive

A neurodegenerative disorder characterized by onset in childhood of slowly progressive spastic paraplegia and cerebellar signs. Some patients have cognitive impairment, cataracts, and cerebral, cerebellar, and corpus callosum atrophy on brain imaging.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
137.0 TPM
Cérebro - Hemisfério cerebelar
119.2 TPM
Tireoide
100.6 TPM
Intestino delgado
98.6 TPM
Pituitária
87.5 TPM
OUTRAS DOENÇAS (2)
hereditary spastic paraplegia 46autosomal recessive cerebellar ataxia with late-onset spasticity
HGNC:18986UniProt:Q9HCG7
SCARB2Lysosome membrane protein 2Candidate gene tested inTolerante
FUNÇÃO

Acts as a lysosomal receptor for glucosylceramidase (GBA1) targeting (Microbial infection) Acts as a receptor for enterovirus 71

LOCALIZAÇÃO

Lysosome membrane

VIAS BIOLÓGICAS (1)
Clathrin-mediated endocytosis
MECANISMO DE DOENÇA

Epilepsy, progressive myoclonic 4, with or without renal failure

A form of progressive myoclonic epilepsy, a clinically and genetically heterogeneous group of disorders defined by the combination of action and reflex myoclonus, other types of epileptic seizures, and progressive neurodegeneration and neurocognitive impairment. EPM4 is an autosomal recessive form associated with renal failure in some cases. Cognitive function is preserved.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
119.7 TPM
Fibroblastos
117.7 TPM
Pulmão
114.5 TPM
Cervix Endocervix
105.3 TPM
Artéria coronária
99.7 TPM
OUTRAS DOENÇAS (3)
action myoclonus-renal failure syndromeGaucher disease type IUnverricht-Lundborg syndrome
HGNC:1665UniProt:Q14108
APOEApolipoprotein EDisease-causing germline mutation(s) inTolerante
FUNÇÃO

APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids (PubMed:14754908, PubMed:1911868, PubMed:6860692). APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance (PubMed:14754908, PubMed:1911868, PubMed:1917954, PubMed:23620513, PubMed:2762297, PubMed:6860692, PubMed:9395455). Apolipoproteins are amphipathic mole

LOCALIZAÇÃO

SecretedSecreted, extracellular spaceSecreted, extracellular space, extracellular matrixExtracellular vesicleEndosome, multivesicular body

VIAS BIOLÓGICAS (9)
Nuclear signaling by ERBB4Scavenging by Class A ReceptorsTranscriptional regulation by the AP-2 (TFAP2) family of transcription factorsChylomicron assemblyHDL remodeling
MECANISMO DE DOENÇA

Hyperlipoproteinemia 3

A disorder characterized by the accumulation of intermediate-density lipoprotein particles (IDL or broad-beta-lipoprotein) rich in cholesterol. Clinical features include xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause.

OUTRAS DOENÇAS (6)
lipoprotein glomerulopathyhyperlipoproteinemia type 3sea-blue histiocyte syndromeAlzheimer disease 2
HGNC:613UniProt:P02649
ASAH1Acid ceramidaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Lysosomal ceramidase that hydrolyzes sphingolipid ceramides into sphingosine and free fatty acids at acidic pH (PubMed:10610716, PubMed:11451951, PubMed:15655246, PubMed:26898341, PubMed:36752535, PubMed:7744740, PubMed:7852294). Ceramides, sphingosine, and its phosphorylated form sphingosine-1-phosphate are bioactive lipids that mediate cellular signaling pathways regulating several biological processes including cell proliferation, apoptosis and differentiation (PubMed:10610716). Has a higher

LOCALIZAÇÃO

LysosomeSecretedNucleusCytoplasm

VIAS BIOLÓGICAS (2)
Glycosphingolipid catabolismRegulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy
MECANISMO DE DOENÇA

Farber lipogranulomatosis

An autosomal recessive lysosomal storage disorder characterized by subcutaneous lipid-loaded nodules, excruciating pain in the joints and extremities, and marked accumulation of ceramide in lysosomes. Disease severity is variable. The most severe disease subtype is a rare neonatal form with death occurring before 1 year of age.

OUTRAS DOENÇAS (2)
spinal muscular atrophy-progressive myoclonic epilepsy syndromeFarber lipogranulomatosis
HGNC:735UniProt:Q13510
ARSAATPase GET3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

ATPase required for the post-translational delivery of tail-anchored (TA) proteins to the endoplasmic reticulum (PubMed:17382883). Recognizes and selectively binds the transmembrane domain of TA proteins in the cytosol. This complex then targets to the endoplasmic reticulum by membrane-bound receptors GET1/WRB and CAMLG/GET2, where the tail-anchored protein is released for insertion. This process is regulated by ATP binding and hydrolysis. ATP binding drives the homodimer towards the closed dime

LOCALIZAÇÃO

CytoplasmEndoplasmic reticulumNucleus, nucleolus

VIAS BIOLÓGICAS (2)
The activation of arylsulfatasesGlycosphingolipid catabolism
MECANISMO DE DOENÇA

Cardiomyopathy, dilated, 2H

A form of dilated cardiomyopathy, a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. CMD2H is an autosomal recessive form characterized by rapid progression and death in early infancy.

OUTRAS DOENÇAS (3)
metachromatic leukodystrophy, juvenile formmetachromatic leukodystrophy, late infantile formmetachromatic leukodystrophy, adult form
HGNC:713UniProt:O43681
HEXBBeta-hexosaminidase subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Hydrolyzes the non-reducing end N-acetyl-D-hexosamine and/or sulfated N-acetyl-D-hexosamine of glycoconjugates, such as the oligosaccharide moieties from proteins and neutral glycolipids, or from certain mucopolysaccharides (PubMed:11707436, PubMed:8123671, PubMed:8672428, PubMed:9694901). The isozyme B does not hydrolyze each of these substrates, however hydrolyzes efficiently neutral oligosaccharide (PubMed:11707436). Only the isozyme A is responsible for the degradation of GM2 gangliosides in

LOCALIZAÇÃO

LysosomeCytoplasmic vesicle, secretory vesicle, Cortical granule

VIAS BIOLÓGICAS (1)
Defective HEXB causes GM2G2 (Hyaluronan metabolism)
MECANISMO DE DOENÇA

GM2-gangliosidosis 2

An autosomal recessive lysosomal storage disease marked by the accumulation of GM2 gangliosides in the neuronal cells. Clinically indistinguishable from GM2-gangliosidosis type 1, presenting startle reactions, early blindness, progressive motor and mental deterioration, macrocephaly and cherry-red spots on the macula.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
137.7 TPM
Aorta
121.2 TPM
Cervix Endocervix
116.9 TPM
Cervix Ectocervix
109.4 TPM
Glândula salivar
107.6 TPM
OUTRAS DOENÇAS (4)
Sandhoff diseaseSandhoff disease, adult formSandhoff disease, infantile formSandhoff disease, juvenile form
HGNC:4879UniProt:P07686
PSAPMitochondrial carrier homolog 1Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Protein insertase that mediates insertion of transmembrane proteins into the mitochondrial outer membrane (PubMed:36264797). Catalyzes insertion of proteins with alpha-helical transmembrane regions, such as signal-anchored, tail-anchored and multi-pass membrane proteins (By similarity). Does not mediate insertion of beta-barrel transmembrane proteins (By similarity). May play a role in apoptosis (PubMed:12377771)

LOCALIZAÇÃO

Mitochondrion outer membrane

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
1575.5 TPM
Baço
1390.0 TPM
Glândula adrenal
1384.0 TPM
Sangue
1315.6 TPM
Cervix Endocervix
1314.5 TPM
OUTRAS DOENÇAS (9)
Gaucher disease due to saposin C deficiencyKrabbe disease due to saposin A deficiencycombined PSAP deficiencymetachromatic leukodystrophy due to saposin B deficiency
HGNC:9498UniProt:Q9NZJ7
GM2AGanglioside GM2 activatorDisease-causing germline mutation(s) inTolerante
FUNÇÃO

The large binding pocket can accommodate several single chain phospholipids and fatty acids, GM2A also exhibits some calcium-independent phospholipase activity (By similarity). Binds gangliosides and stimulates ganglioside GM2 degradation. It stimulates only the breakdown of ganglioside GM2 and glycolipid GA2 by beta-hexosaminidase A. It extracts single GM2 molecules from membranes and presents them in soluble form to beta-hexosaminidase A for cleavage of N-acetyl-D-galactosamine and conversion

LOCALIZAÇÃO

Lysosome

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

GM2-gangliosidosis AB

An autosomal recessive lysosomal storage disease marked by the accumulation of GM2 gangliosides in the neuronal cells. It is characterized by GM2 gangliosides accumulation in the presence of both normal hexosaminidase A and B.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
105.2 TPM
Vagina
90.7 TPM
Skin Not Sun Exposed Suprapubic
85.3 TPM
Skin Sun Exposed Lower leg
78.9 TPM
Esôfago - Mucosa
77.5 TPM
INTERAÇÕES PROTEICAS (5)
OUTRAS DOENÇAS (1)
Tay-Sachs disease AB variant
HGNC:4367UniProt:P17900
GLB1Beta-galactosidaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Cleaves beta-linked terminal galactosyl residues from gangliosides, glycoproteins, and glycosaminoglycans Has no beta-galactosidase catalytic activity, but plays functional roles in the formation of extracellular elastic fibers (elastogenesis) and in the development of connective tissue. Seems to be identical to the elastin-binding protein (EBP), a major component of the non-integrin cell surface receptor expressed on fibroblasts, smooth muscle cells, chondroblasts, leukocytes, and certain cance

LOCALIZAÇÃO

LysosomeCytoplasm, perinuclear region

VIAS BIOLÓGICAS (5)
Sialic acid metabolismGlycosphingolipid catabolismCS/DS degradationKeratan sulfate degradationDefective NEU1 causes sialidosis
MECANISMO DE DOENÇA

GM1-gangliosidosis 1

An autosomal recessive lysosomal storage disease marked by the accumulation of GM1 gangliosides, glycoproteins and keratan sulfate primarily in neurons of the central nervous system. GM1-gangliosidosis type 1 is characterized by onset within the first three months of life, central nervous system degeneration, coarse facial features, hepatosplenomegaly, skeletal dysmorphology reminiscent of Hurler syndrome, and rapidly progressive psychomotor deterioration. Urinary oligosaccharide levels are high. It leads to death usually between the first and second year of life.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
68.5 TPM
Tireoide
44.2 TPM
Glândula adrenal
40.6 TPM
Cervix Endocervix
35.2 TPM
Pulmão
35.1 TPM
OUTRAS DOENÇAS (4)
mucopolysaccharidosis type 4BGM1 gangliosidosis type 2GM1 gangliosidosis type 3GM1 gangliosidosis type 1
HGNC:4298UniProt:P16278
NPC2NPC intracellular cholesterol transporter 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Intracellular cholesterol transporter which acts in concert with NPC1 and plays an important role in the egress of cholesterol from the lysosomal compartment (PubMed:11125141, PubMed:15937921, PubMed:17018531, PubMed:18772377, PubMed:29580834). Unesterified cholesterol that has been released from LDLs in the lumen of the late endosomes/lysosomes is transferred by NPC2 to the cholesterol-binding pocket in the N-terminal domain of NPC1 (PubMed:17018531, PubMed:18772377, PubMed:27238017). May bind

LOCALIZAÇÃO

SecretedEndoplasmic reticulumLysosome

VIAS BIOLÓGICAS (1)
Neutrophil degranulation
MECANISMO DE DOENÇA

Niemann-Pick disease C2

A lysosomal storage disorder that affects the viscera and the central nervous system. It is due to defective intracellular processing and transport of low-density lipoprotein derived cholesterol. It causes accumulation of cholesterol in lysosomes, with delayed induction of cholesterol homeostatic reactions. Niemann-Pick disease type C2 has a highly variable clinical phenotype. Clinical features include variable hepatosplenomegaly and severe progressive neurological dysfunction such as ataxia, dystonia and dementia. The age of onset can vary from infancy to late adulthood.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
220.1 TPM
Pulmão
217.6 TPM
Cervix Endocervix
153.6 TPM
Ovário
144.8 TPM
Aorta
132.6 TPM
OUTRAS DOENÇAS (6)
Niemann-Pick disease, type C2Niemann-Pick disease type C, severe perinatal formNiemann-Pick disease type C, severe early infantile neurologic onsetNiemann-Pick disease type C, juvenile neurologic onset
HGNC:14537UniProt:P61916
GALCGalactocerebrosidaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Hydrolyzes the galactose ester bonds of glycolipids such as galactosylceramide and galactosylsphingosine (PubMed:8281145, PubMed:8399327). Enzyme with very low activity responsible for the lysosomal catabolism of galactosylceramide, a major lipid in myelin, kidney and epithelial cells of small intestine and colon (PubMed:8281145, PubMed:8399327)

LOCALIZAÇÃO

Lysosome

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

Krabbe disease

An autosomal recessive disorder characterized by insufficient catabolism of several galactolipids that are important for normal myelin production. Four clinical forms are recognized. The infantile form accounts for 90% of cases. It manifests before six months of age with irritability, spasticity, arrest of motor and mental development, and bouts of temperature elevation without infection. This is followed by myoclonic jerks of arms and legs, oposthotonus, hypertonic fits, and mental regression, which progresses to a severe decerebrate condition with no voluntary movements and death from respiratory infections or cerebral hyperpyrexia before 2 years of age. Cases with later onset present with unexplained blindness, weakness and sensorimotor peripheral neuropathy, mental deterioration and death.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
31.7 TPM
Testículo
28.0 TPM
Brain Spinal cord cervical c-1
26.5 TPM
Pulmão
25.7 TPM
Ovário
22.2 TPM
OUTRAS DOENÇAS (4)
Krabbe diseaseinfantile Krabbe diseaseadult Krabbe diseaselate-infantile/juvenile Krabbe disease
HGNC:4115UniProt:P54803
GLAN-acetyltransferase 8Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Endoplasmic reticulum (ER)-membrane-bound lysine N-acetyltransferase catalyzing the N6-acetylation of lysine residues in the lumen of the ER in various proteins, including PROM1 and BACE1, using acetyl-CoA as acetyl donor (PubMed:19011241, PubMed:22267734, PubMed:24556617, PubMed:31945187). Thereby, may regulate apoptosis through the acetylation and the regulation of the expression of PROM1 (PubMed:24556617). May also regulate amyloid beta-peptide secretion through acetylation of BACE1 and the r

LOCALIZAÇÃO

Endoplasmic reticulum-Golgi intermediate compartment membraneEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
34.6 TPM
Linfócitos
33.0 TPM
Sangue
31.3 TPM
Glândula adrenal
24.7 TPM
Baço
24.7 TPM
OUTRAS DOENÇAS (1)
Fabry disease
HGNC:4296UniProt:Q9UHE5
HEXABeta-hexosaminidase subunit alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Hydrolyzes the non-reducing end N-acetyl-D-hexosamine and/or sulfated N-acetyl-D-hexosamine of glycoconjugates, such as the oligosaccharide moieties from proteins and neutral glycolipids, or from certain mucopolysaccharides (PubMed:11707436, PubMed:8123671, PubMed:8672428, PubMed:9694901). The isozyme S is as active as the isozyme A on the anionic bis-sulfated glycans, the chondroitin-6-sulfate trisaccharide (C6S-3), and the dermatan sulfate pentasaccharide, and the sulfated glycosphingolipid SM

LOCALIZAÇÃO

Lysosome

VIAS BIOLÓGICAS (1)
Defective HEXA causes GM2G1 (Hyaluronan metabolism)
MECANISMO DE DOENÇA

GM2-gangliosidosis 1

An autosomal recessive lysosomal storage disease marked by the accumulation of GM2 gangliosides in the neuronal cells. It is characterized by GM2 gangliosides accumulation in the absence of HEXA activity, leading to neurodegeneration and, in the infantile form, death in early childhood. It exists in several forms: infantile (most common and most severe), juvenile and adult (late-onset).

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
43.9 TPM
Fibroblastos
39.7 TPM
Cervix Endocervix
36.7 TPM
Aorta
36.0 TPM
Pulmão
34.0 TPM
OUTRAS DOENÇAS (4)
Tay-Sachs diseaseTay-Sachs disease, b variant, infantile formTay-Sachs disease, B variant, adult formTay-Sachs disease, b variant, juvenile form
HGNC:4878UniProt:P06865
NPC1NPC intracellular cholesterol transporter 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Intracellular cholesterol transporter which acts in concert with NPC2 and plays an important role in the egress of cholesterol from the endosomal/lysosomal compartment (PubMed:10821832, PubMed:12554680, PubMed:18772377, PubMed:27238017, PubMed:9211849, PubMed:9927649). Unesterified cholesterol that has been released from LDLs in the lumen of the late endosomes/lysosomes is transferred by NPC2 to the cholesterol-binding pocket in the N-terminal domain of NPC1 (PubMed:18772377, PubMed:19563754, Pu

LOCALIZAÇÃO

Late endosome membraneLysosome membrane

VIAS BIOLÓGICAS (1)
LDL clearance
MECANISMO DE DOENÇA

Niemann-Pick disease C1

A lysosomal storage disorder that affects the viscera and the central nervous system. It is due to defective intracellular processing and transport of low-density lipoprotein derived cholesterol. It causes accumulation of cholesterol in lysosomes, with delayed induction of cholesterol homeostatic reactions. Niemann-Pick disease type C1 has a highly variable clinical phenotype. Clinical features include variable hepatosplenomegaly and severe progressive neurological dysfunction such as ataxia, dystonia and dementia. The age of onset can vary from infancy to late adulthood. An allelic variant of Niemann-Pick disease type C1 is found in people with Nova Scotia ancestry. Patients with the Nova Scotian clinical variant are less severely affected.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
39.4 TPM
Fibroblastos
32.1 TPM
Glândula adrenal
31.5 TPM
Pulmão
30.3 TPM
Nervo tibial
24.6 TPM
OUTRAS DOENÇAS (6)
Niemann-Pick disease, type C1Niemann-Pick disease type C, late infantile neurologic onsetNiemann-Pick disease type C, juvenile neurologic onsetNiemann-Pick disease type C, severe perinatal form
HGNC:7897UniProt:O15118
SMPD1Sphingomyelin phosphodiesteraseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Converts sphingomyelin to ceramide (PubMed:12563314, PubMed:1840600, PubMed:18815062, PubMed:25339683, PubMed:25920558, PubMed:27659707, PubMed:33163980). Exists as two enzymatic forms that arise from alternative trafficking of a single protein precursor, one that is targeted to the endolysosomal compartment, whereas the other is released extracellularly (PubMed:20807762, PubMed:21098024, PubMed:9660788). However, in response to various forms of stress, lysosomal exocytosis may represent a major

LOCALIZAÇÃO

LysosomeLipid dropletSecretedSecreted, extracellular space

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

Niemann-Pick disease A

An early-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder characterized by onset within the first year of life, intellectual disability, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
79.4 TPM
Tireoide
67.2 TPM
Pituitária
65.9 TPM
Aorta
63.0 TPM
Cerebelo
61.4 TPM
OUTRAS DOENÇAS (2)
Niemann-Pick disease type BNiemann-Pick disease type A
HGNC:11120UniProt:P17405
SUMF1Formylglycine-generating enzymeDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Oxidase that catalyzes the conversion of cysteine to 3-oxoalanine on target proteins, using molecular oxygen and an unidentified reducing agent (PubMed:12757706, PubMed:15657036, PubMed:15907468, PubMed:16368756, PubMed:21224894, PubMed:25931126). 3-oxoalanine modification, which is also named formylglycine (fGly), occurs in the maturation of arylsulfatases and some alkaline phosphatases that use the hydrated form of 3-oxoalanine as a catalytic nucleophile (PubMed:12757706, PubMed:15657036, PubM

LOCALIZAÇÃO

Endoplasmic reticulum lumen

VIAS BIOLÓGICAS (2)
The activation of arylsulfatasesGlycosphingolipid catabolism
MECANISMO DE DOENÇA

Multiple sulfatase deficiency

A clinically and biochemically heterogeneous disorder caused by the simultaneous impairment of all sulfatases, due to defective post-translational modification and activation. It combines features of individual sulfatase deficiencies such as metachromatic leukodystrophy, mucopolysaccharidosis, chondrodysplasia punctata, hydrocephalus, ichthyosis, neurologic deterioration and developmental delay.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
20.9 TPM
Aorta
17.9 TPM
Tireoide
16.0 TPM
Artéria coronária
14.4 TPM
Esôfago - Mucosa
13.6 TPM
OUTRAS DOENÇAS (1)
mucosulfatidosis
HGNC:20376UniProt:Q8NBK3

Medicamentos e terapias

MIGALASTAT HYDROCHLORIDEPhase 4

Mecanismo: Alpha-galactosidase A stabiliser

MIGLUSTATPhase 4

Mecanismo: Ceramide glucosyltransferase inhibitor

ELIGLUSTATPhase 4

Mecanismo: Ceramide glucosyltransferase inhibitor

TORIPALIMABPhase 4

Mecanismo: Programmed cell death protein 1 antagonist

ATIDARSAGENE AUTOTEMCELPhase 4

Mecanismo: ARSA exogenous gene

VENGLUSTATPhase 3

Mecanismo: Ceramide glucosyltransferase inhibitor

MIGALASTATPhase 3

Mecanismo: Alpha-galactosidase A stabiliser

LUCERASTATPhase 3

Mecanismo: Ceramide glucosyltransferase inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

627 variantes patogênicas registradas no ClinVar.

🧬 GBA1: NM_000157.4(GBA1):c.518C>T (p.Thr173Ile) ()
🧬 GBA1: NC_000001.10:g.(?_155204242)_(155209869_155210420)del ()
🧬 GBA1: NM_000157.4(GBA1):c.745del (p.Ala249fs) ()
🧬 GBA1: GRCh37/hg19 1q21.1-44(chr1:143932350-249224684)x3 ()
🧬 GBA1: GRCh37/hg19 1q21.3-22(chr1:154822196-156304685)x3 ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 2 variantes classificadas pelo ClinVar.

1
1
Patogênica (50.0%)
VUS (50.0%)
VARIANTES MAIS SIGNIFICATIVAS
ASAH1: NM_004315.6(ASAH1):c.35G>C (p.Arg12Pro) [Conflicting classifications of pathogenicity]
ASAH1: NM_177924.5(ASAH1):c.1163G>A (p.Cys388Tyr) [Uncertain significance]

Vias biológicas (Reactome)

44 vias biológicas associadas aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado5
3Fase 33
Medicamentos catalogadosEnsaios clínicos· 8 medicamentos · 0 ensaios
✓ Aprovados — podem ser usados hoje
MIGALASTAT HYDROCHLORIDEMIGLUSTATELIGLUSTATTORIPALIMABATIDARSAGENE AUTOTEMCEL
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Esfingolipidose

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
65 papers (10 anos)
#1

Brain accumulation of lactosylceramide characterizes GALC deficiency in a zebrafish model of Krabbe disease.

Brain : a journal of neurology2025 Oct 03

Krabbe disease (KD) is an autosomal recessive sphingolipidosis due to mutations of the GALC gene encoding for the lysosomal β-galactosylceramidase (GALC) that removes β-galactose from β-galactosylceramide, β-lactosylceramide (LacCer) and the neurotoxic metabolite β-galactosylsphingosine (psychosine). At present, the accumulation of psychosine is thought to be the main cause of demyelination, neurodegeneration and neuroinflammation that characterize the early infantile KD with a 1.5-2-year median survival. Currently, the standard of care of KD is haematopoietic stem cell transplantation which, however, improves the lifespan of Krabbe patients only when performed before symptoms appear. Thus, a better understanding of the pathogenesis of KD is required for the development of more efficacious therapeutic approaches. This largely depends upon the availability of novel suitable animal models of the disease. Zebrafish (Danio rerio) represents a useful platform for the study of the mechanisms responsible for human hereditary diseases, including sphingolipidoses, and for the identification of new therapeutics. Two co-orthologues of human GALC have been identified in zebrafish, named galca and galcb. Here, we generated a mutant zebrafish line for each of the two co-orthologues by CRISPR/Cas9 genome editing. Galcb knockout (KO), but not galca KO, exerts a dramatic decrease of total GALC activity both in zebrafish embryos and in the brain of adult mutants. At 3-4 months post-fertilization, galcb KO zebrafish showed impaired locomotion and reduced lifespan. Gene expression analysis, immunohistochemistry, spectral confocal reflectance and transmission electron microscopy showed the presence of demyelination, neuroinflammation and neurodegeneration in the brain of galcb KO mutants. Notably, double galca/galcb KO did not cause a further worsening of the disease when compared with galcb KO mutants. Finally, targeted lipidomic analysis demonstrated a dramatic accumulation of the bioactive sphingolipid LacCer in the brain of both galcb KO and double galca/galcb KO mutants with a modest increase of psychosine levels. Accordingly, activation of LacCer-related signalling occurs in the brain of galcb KO animals. Furthermore, intraventricular injection of LacCer upregulates the expression of various proinflammatory markers and increase mpeg1-positive macrophage infiltration in the brain of 5 dpf zebrafish embryos. In conclusion, galcb KO zebrafish recapitulates several pathological features of KD and is characterized by the accumulation of the bioactive LacCer. This model sheds new light on a possible role of LacCer as a neuroinflammatory/neurodegenerative metabolite in KD with implications for the development of novel therapeutic strategies.

#2

Cytotoxic lymphocyte effector function is unaffected in patients with Gaucher disease.

Frontiers in immunology2025

Gaucher disease (GD) is one of the most common lysosomal storage disorders. It is caused by bi-allelic mutations in the GBA1 gene responsible for the production of β-glucocerebrosidase, an enzyme responsible for the hydrolysis of the sphingolipid glucocerebroside. This results in its accumulation in various organs, and patients can present with a variety of symptoms ranging from visceral enlargement, bone pathology and hematological manifestations. Neuronopathic effects are seen in the severe form of the disease. GD patients also have an increased risk of B-cell malignancies. Some of the hematological symptoms of GD resemble those of the systemic hyperinflammatory condition, hemophagocytic lymphohistiocytosis (HLH). HLH can be familial, due to functional deficiencies in cytotoxic lymphocytes, or acquired from a variety of causes ranging from infections to blood cancers. While patients with inherited and acquired HLH receive the same first-line therapy, patients with the familial form can only be cured by stem cell transplantation, although this treatment may be detrimental to patients with the acquired form of the disease. Therefore, we investigated whether the abnormal lipid accumulation in GD patient cytotoxic lymphocytes and in cells with irreversibly inhibited glucocerebrosidase activity affects their cytotoxicity. Our detailed analysis of primary cytotoxic T lymphocytes and natural killer cells revealed that the activity of these cells was not affected. This finding has important implications for the treatment choices for patients with GD and suggests that these patients can be treated with autologous immunotherapy if they develop hematological cancers.

#3

Therapeutic targeting of neuroinflammation in sphingolipidosis.

Molecular immunology2025 Nov

Lysosomal storage diseases (LSDs) are a class of hereditary metabolic disorders primarily caused by lysosomal enzyme defects, leading to the accumulation of undegraded substrates. Sphingolipidoses, a subset of LSDs, are primarily associated with profound involvement of the central nervous system (CNS), characterized by progressive neurodegeneration due to massive sphingolipid accumulation. A common pathological feature among many CNS-involved LSDs is the early activation of microglia and astrocytes, which often precedes and predicts regions of subsequent neuronal loss. The extent to which neuroinflammation disrupts CNS homeostasis appears to be determined by its onset, magnitude, and duration. Although neuroinflammatory processes are increasingly recognized as critical contributors to disease progression in sphingolipidoses, the molecular mechanisms underlying glial activation and the initiation of inflammatory cascades remain incompletely understood. Therefore, mouse models of sphingolipidoses have been instrumental in elucidating these pathogenic processes and provide valuable platforms for evaluating therapeutic strategies. This review critically examines the role of neuroinflammation in sphingolipidoses, summarizes insights derived from pre-clinical models, and discusses the therapeutic potential of anti-inflammatory interventions to mitigate CNS pathology and improve clinical outcomes.

#4

Expert review in diagnostic, therapeutic and follow-up of Fabry disease in Latin America based on patient care standards.

Molecular genetics and metabolism reports2025 Jun

Fabry disease (FD) is an X-linked lysosomal sphingolipidosis. It is caused by pathogenic variants in the GLA gene with a consequent deficiency of the enzyme α-galactosidase A, resulting in the pathological accumulation of glycolipids - mainly globotriosyl ceramide (GL-3, GB3) and its deacylated product, globotriaosylsphingosine (Lyso-Gb-3) - in plasma and in a wide variety of cell types throughout the human body; it is characterized as a chronic, multisystemic disease with progressive evolution, which causes deterioration of the patient's quality of life and decreases survival and life expectancy.In Latin America there are different limitations to the management of patients with Fabry disease, in most countries, access to diagnostic tools and treatment on time is complex and can sometimes suffer delays in its implementation. This situation is due to the high costs to health systems of follow-up and pharmacological therapy for Fabry patients, creating barriers to timely access. Although medical criteria are fundamental in the choice of pharmacological therapy, the final decision should also rely on the patient's choice according to their expectations and the adherence and compliance with the treatment that they are willing to follow. As it has been described, there are currently three therapeutic options, for which the appropriate profile must be defined to achieve the best clinical outcomes, considering that it is a permanent treatment; experts consider that Fabry patients need comprehensive and interdisciplinary management to stop the progression and functional deterioration of the affected organs by its multiple systemic manifestations. In Latin-American countries, it is difficult to guarantee this comprehensive and coordinated management, due to limited public policies related to orphan diseases diagnosis, treatment and follow up.It is considered crucial to structure support networks specialized in Fabry disease and generate partnerships with health institutions and other health system stakeholders, that would articulate and coordinate patients and relatives counseling and management, establish the specific pharmacological treatment to reduce the progression of the disease and the systemic involvement, deciding between the administration of enzyme replacement therapy or the most recent option of oral management with pharmacological chaperone both with proven effectiveness. This will be the decision of the attending physician, who will propose and advise the therapeutic choice that best suits the patient's needs.

#5

Evaluation of Lysosphingolipid Analysis for the Diagnosis of Lysosomal Storage Disease.

Klinische Padiatrie2025 Jul

Lysosomal storage disorders (LSD) are a group of inherited inborn metabolism errors that are characterized by a deficiency in the lysosomal enzyme. In patients with suspected lipid storage disorders, confirmation of the diagnosis relies predominantly on the measurement of specific enzymatic activities and molecular genetic studies. New approaches to the measurement of lysosphingolipids have been developed that may serve as a rapid first-tier screening tests for the evaluation of lysosomal storage disorders. The present study evaluates the results of lysosphingolipid screening tests in patients with suspected lysosomal storage diseases. Lysosphingolipid elevation was detected in five patients examined with suspected lysosomal storage disease, and a definitive diagnosis was reached based on genetic analysis. Our data support recent evidence of the primary role of LysoSLs in the diagnosis of sphingolipidosis, and suggest that these biomarkers may be used for diagnosis and treatment monitoring in the future. Lysosomale Speicherstörungen (LSD) sind eine Gruppe erblicher angeborener Stoffwechselstörungen, die durch einen Mangel des lysosomalen Enzyms gekennzeichnet sind. Bei Patienten mit Verdacht auf Lipidspeicherstörungen stützt sich die Diagnosesicherung überwiegend auf die Messung spezifischer enzymatischer Aktivitäten und molekulargenetische Untersuchungen. Es wurden neue Ansätze zur Messung von Lysosphingolipiden entwickelt, die als schnelle Screening-Tests der ersten Stufe zur Beurteilung lysosomaler Speicherstörungen dienen können. Die vorliegende Studie wertet die Ergebnisse von Lysosphingolipid-Screeningtests bei Patienten mit Verdacht auf lysosomale Speicherkrankheiten aus. Bei fünf untersuchten Patienten mit Verdacht auf eine lysosomale Speicherkrankheit wurde ein Anstieg des Lysosphingolipids festgestellt, und auf der Grundlage einer genetischen Analyse konnte eine endgültige Diagnose gestellt werden. Unsere Daten stützen aktuelle Hinweise auf die primäre Rolle von LysoSLs bei der Diagnose von Sphingolipidose und legen nahe, dass diese Biomarker in Zukunft für die Diagnose und Behandlungsüberwachung verwendet werden könnten.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC43 artigos no totalmostrando 63

2025

Cytotoxic lymphocyte effector function is unaffected in patients with Gaucher disease.

Frontiers in immunology
2025

Therapeutic targeting of neuroinflammation in sphingolipidosis.

Molecular immunology
2025

Brain accumulation of lactosylceramide characterizes GALC deficiency in a zebrafish model of Krabbe disease.

Brain : a journal of neurology
2025

Expert review in diagnostic, therapeutic and follow-up of Fabry disease in Latin America based on patient care standards.

Molecular genetics and metabolism reports
2025

Evaluation of Lysosphingolipid Analysis for the Diagnosis of Lysosomal Storage Disease.

Klinische Padiatrie
2024

Development of a Multiplexed Sphingolipids Method for Diagnosis of Inborn Errors of Ceramide Metabolism.

Clinical chemistry
2024

Expanding the Neurological Phenotype of Anderson-Fabry Disease: Proof of Concept for an Extrapyramidal Neurodegenerative Pattern and Comparison with Monogenic Vascular Parkinsonism.

Cells
2024

Impact of an irreversible β-galactosylceramidase inhibitor on the lipid profile of zebrafish embryos.

Computational and structural biotechnology journal
2024

Improving newborn screening test performance for metachromatic leukodystrophy: Recommendation from a pre-pilot study that identified a late-infantile case for treatment.

Molecular genetics and metabolism
2024

Selective screening for inherited metabolic disorders in a tertiary care hospital of Karachi - A retrospective chart review.

Pakistan journal of medical sciences
2023

Altered Sphingolipid Hydrolase Activities and Alpha-Synuclein Level in Late-Onset Schizophrenia.

Metabolites
2023

[Multisystem lesions in orphan diseases: rheumatological aspects of Fabry's disease. Case report].

Terapevticheskii arkhiv
2023

Animal Models for the Study of Gaucher Disease.

International journal of molecular sciences
2023

Lysoglycosphingolipids have the ability to induce cell death through direct PI3K inhibition.

Journal of neurochemistry
2023

The atypical sphingolipid SPB 18:1(14Z);O2 is a biomarker for DEGS1 related hypomyelinating leukodystrophy.

Journal of lipid research
2023

Alpha-Synuclein mRNA Level Found Dependent on L444P Variant in Carriers and Gaucher Disease Patients on Enzyme Replacement Therapy.

Biomolecules
2023

A zebrafish model of combined saposin deficiency identifies acid sphingomyelinase as a potential therapeutic target.

Disease models &amp; mechanisms
2023

Importance to include differential diagnostics for acid sphingomyelinase deficiency (ASMD) in patients suspected to have to Gaucher disease.

Molecular genetics and metabolism
2023

Gene Therapy of Sphingolipid Metabolic Disorders.

International journal of molecular sciences
2022

Potential Role of Sphingolipidoses-Associated Lysosphingolipids in Cancer.

Cancers
2022

β-Galactosylceramidase Deficiency Causes Upregulation of Long Pentraxin-3 in the Central Nervous System of Krabbe Patients and Twitcher Mice.

International journal of molecular sciences
2023

A rare cause of nephrotic syndrome-sphingosine-1-phosphate lyase (SGPL1) deficiency: 6 cases and a review of the literature.

Pediatric nephrology (Berlin, Germany)
2022

Hematological Findings in Lysosomal Storage Disorders: A Perspective from the Medical Laboratory.

EJIFCC
2022

A 2-bp deletion mutation in SMPD1 gene leading to lysosomal acid sphingomyelinase deficiency in a Chinese consanguineous pedigree.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2022

Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patients.

Molecular genetics and metabolism reports
2022

Lysosphingolipid urine screening test using mass spectrometry for the early detection of lysosomal storage disorders.

Bioanalysis
2021

Reproduction in Animal Models of Lysosomal Storage Diseases: A Scoping Review.

Frontiers in molecular biosciences
2021

The Association Between Lysosomal Storage Disorder Genes and Parkinson's Disease: A Large Cohort Study in Chinese Mainland Population.

Frontiers in aging neuroscience
2022

Analysis of the HEXA, HEXB, ARSA, and SMPD1 Genes in 68 Iranian Patients.

Journal of molecular neuroscience : MN
2021

The incidence rate of hospitalized lysosomal storage diseases in Poland in 2013-2015 based on data from the National Health Fund.

Pediatric endocrinology, diabetes, and metabolism
2021

Expression of Ripk1 and DAM genes correlates with severity and progression of Krabbe disease.

Human molecular genetics
2021

Exploiting the Potential of Drosophila Models in Lysosomal Storage Disorders: Pathological Mechanisms and Drug Discovery.

Biomedicines
2020

The role of exosome lipids in central nervous system diseases.

Reviews in the neurosciences
2020

Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification.

International journal of molecular sciences
2020

Responsiveness of sphingosine phosphate lyase insufficiency syndrome to vitamin B6 cofactor supplementation.

Journal of inherited metabolic disease
2020

Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson's Disease.

Journal of clinical medicine
2019

β-Galactosylceramidase Deficiency Causes Bone Marrow Vascular Defects in an Animal Model of Krabbe Disease.

International journal of molecular sciences
2020

Primary adrenal insufficiency: New genetic causes and their long-term consequences.

Clinical endocrinology
2019

A novel association between angiokeratoma corporis diffusum and acid sphingomyelinase deficiency.

Pediatric dermatology
2019

Clinical findings in Brazilian patients with adult GM1 gangliosidosis.

JIMD reports
2019

DEGS1 variant causes neurological disorder.

European journal of human genetics : EJHG
2019

Quantification of 3D Brain Microangioarchitectures in an Animal Model of Krabbe Disease.

International journal of molecular sciences
2019

Fabry disease in cardiology practice: Literature review and expert point of view.

Archives of cardiovascular diseases
2019

Defective Sphingolipids Metabolism and Tumor Associated Macrophages as the Possible Links Between Gaucher Disease and Blood Cancer Development.

International journal of molecular sciences
2019

ROS Scavenger, Ebselen, Has No Preventive Effect in New Hearing Loss Model Using a Cholesterol-Chelating Agent.

Journal of audiology &amp; otology
2019

SGPL1 Deficiency: A Rare Cause of Primary Adrenal Insufficiency.

The Journal of clinical endocrinology and metabolism
2018

[Gaucher's disease - an overview about a sphingolipidosis].

Therapeutische Umschau. Revue therapeutique
2018

Correlations Between Serum Cholesterol and Vascular Lesions in Fabry Disease Patients.

Circulation journal : official journal of the Japanese Circulation Society
2019

Sphingosine phosphate lyase insufficiency syndrome (SPLIS): A novel inborn error of sphingolipid metabolism.

Advances in biological regulation
2018

Niemann-Pick type C disease: The atypical sphingolipidosis.

Advances in biological regulation
2018

Nephrotic syndrome and adrenal insufficiency caused by a variant in SGPL1.

Clinical kidney journal
2018

Acid ceramidase deficiency: Farber disease and SMA-PME.

Orphanet journal of rare diseases
2017

Pulmonary Involvement in Adult Patients with Inborn Errors of Metabolism.

Respiration; international review of thoracic diseases
2017

Diastereomer-specific quantification of bioactive hexosylceramides from bacteria and mammals.

Journal of lipid research
2017

Krabbe Disease: Report of a Rare Lipid Storage and Neurodegenerative Disorder.

Cureus
2016

Port-to-port delivery: Mobilization of toxic sphingolipids via extracellular vesicles.

Journal of neuroscience research
2016

Lysosphingolipids and sphingolipidoses: Psychosine in Krabbe's disease.

Journal of neuroscience research
2016

Thirteen year retrospective review of the spectrum of inborn errors of metabolism presenting in a tertiary center in Saudi Arabia.

Orphanet journal of rare diseases
2016

Animal models of GM2 gangliosidosis: utility and limitations.

The application of clinical genetics
2016

Niemann-Pick type C: focus on the adolescent/adult onset form.

The International journal of neuroscience
2017

RP-CARS reveals molecular spatial order anomalies in myelin of an animal model of Krabbe disease.

Journal of biophotonics
2015

Treatment of Massive Labial and Gingival Hypertrophy in a Patient With Infantile Systemic Hyalinosis-A Case Report.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
2015

Lysosomal Storage Diseases-Regulating Neurodegeneration.

Journal of experimental neuroscience

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Esfingolipidose.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Esfingolipidose

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Brain accumulation of lactosylceramide characterizes GALC deficiency in a zebrafish model of Krabbe disease.
    Brain : a journal of neurology· 2025· PMID 40305757mais citado
  2. Cytotoxic lymphocyte effector function is unaffected in patients with Gaucher disease.
    Frontiers in immunology· 2025· PMID 41181118mais citado
  3. Therapeutic targeting of neuroinflammation in sphingolipidosis.
    Molecular immunology· 2025· PMID 40992103mais citado
  4. Expert review in diagnostic, therapeutic and follow-up of Fabry disease in Latin America based on patient care standards.
    Molecular genetics and metabolism reports· 2025· PMID 40276562mais citado
  5. Evaluation of Lysosphingolipid Analysis for the Diagnosis of Lysosomal Storage Disease.
    Klinische Padiatrie· 2025· PMID 39321830mais citado
  6. Altered bone structure in Niemann-Pick Type C1 mice, especially in females.
    Bone· 2026· PMID 41932416recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:79225(Orphanet)
  2. MONDO:0019255(MONDO)
  3. GARD:7672(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q2309612(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Esfingolipidose
Compêndio · Raras BR

Esfingolipidose

ORPHA:79225 · MONDO:0019255
CID-11
Medicamentos
8 registrados
MedGen
UMLS
C0037899
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades